急性缺血性卒中溶栓后远程缺血后适应的安全性与疗效
单中心随机对照试验纳入接受静脉溶栓的急性缺血性卒中患者,比较住院期间远程缺血后适应(RIPC)与对照的疗效。RIPC组34例、对照组34例,90天mRS 0-1分比例分别为71.9%与50.0%(校正OR 9.85,95%CI 1.54-63.16;p=0.016)。RIPC组血浆S100-β更低、血管内皮生长因子更高。
要点
- RIPC联合静脉溶栓可改善急性缺血性卒中90天神经功能恢复
- 90天mRS 0-1分比例RIPC组71.9%高于对照组50.0%
- RIPC组S100-β降低、VEGF升高,提示神经保护相关
核心结论
- 重复RIPC联合静脉溶栓可显著促进急性缺血性卒中患者神经功能恢复并改善临床预后。
研究设计与样本
- 单中心随机对照试验,纳入接受静脉溶栓的急性缺血性卒中患者,RIPC组34例、对照组34例。
主要发现
- 90天mRS 0-1分比例RIPC组71.9%、对照组50.0%(校正OR 9.85,95%CI 1.54-63.16;p=0.016)。
- RIPC组血浆S100-β显著低于对照组(p=0.007),血管内皮生长因子显著高于对照组(p=0.003)。
- 两组入院时NIHSS评分(p=0.364)及发病至治疗时间(p=0.889)无显著差异,平均住院时间11.2天。
关键数值与推荐
- 主要终点为90天mRS评分0或1分。
- 研究证据等级为Class IV,提示RIPC可提高90天mRS 0-1分患者比例。
- 临床试验注册号NCT03218293。
临床怎么用
- 对接受静脉溶栓的急性缺血性卒中患者,可考虑住院期间联合重复RIPC以改善90天功能预后。
局限性
- 单中心随机对照试验,样本量较小(每组34例),证据等级为Class IV。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the effect of remote ischemic postconditioning (RIPC) on patients with acute ischemic stroke (AIS) undergoing IV thrombolysis (IVT). METHODS: A single-center randomized controlled trial was performed with patients with AIS receiving IVT. Patients in the RIPC group were administered RIPC treatment (after IVT) during hospitalization. The primary endpoint was a score of 0 or 1 on the modified Rankin scale (mRS) at day 90. The safety, tolerability, and neuroprotection biomarkers associated with RIPC were also evaluated. RESULTS: We collected data from both the RIPC group (n = 34) and the control group (n = 34). The average duration of hospitalization was 11.2 days. There was no significant difference between 2 groups at admission for the NIH Stroke Scale score (p = 0.364) or occur-to-treatment time (p = 0.889). Favorable recovery (mRS score 0-1) at 3 months was obtained in 71.9% of patients in the RIPC group vs 50.0% in the control group (adjusted odds ratio 9.85, 95% confidence interval 1.54-63.16; p = 0.016). We further found significantly lower plasma S100-β (p = 0.007) and higher vascular endothelial growth factor (p = 0.003) levels in the RIPC group than in the control group. CONCLUSIONS: Repeated RIPC combined with IVT can significantly facilitate recovery of nerve function and improve clinical prognosis of patients with AIS. CLINICALTRIALSGOV IDENTIFIER: NCT03218293. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that RIPC after tissue plasminogen activator treatment of AIS significantly increases the proportion of patients with an MRS score of 0 or 1 at 90 days.
引用
- An JQ, Cheng YW, Guo YC, et al. Safety and efficacy of remote ischemic postconditioning after thrombolysis in patients with stroke. Neurology. 2020. PMID: 33028663. doi:10.1212/WNL.0000000000010884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。